Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Biologic treatment for atopic dermatitis appeared to improve growth trajectories for younger children, a trial analysis ...

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

Discover a proof-of-concept study that was conducted to explore whether dupilumab could induce desensitisation to peanut.

The FDA has approved these four biologics to treat atopic dermatitis: dupilumab, lebrikizumab, nemolizumab, and tralokinumab. They are all types of biologics called monoclonal antibodies.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...